PHARMACY

BioPlus adds 2-hour guarantee to patient referrals

BY Alaric DeArment

ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy will notify physicians within two hours whether a patient has been accepted for treatment, the company said.

BioPlus said the new "2-Hour Patient Acceptance Guarantee" program would let physicians know if their patients could be admitted pending insurance qualifications or would not be admitted and triaged to another pharmacy.

"Patients who are referred to a specialty pharmacy face complex conditions," BioPlus senior director of admissions Amanda Brown said. "It’s a scary time for patients, and the last thing they need is to wait days wondering if their specialty — and possibly life-saving — medication can be filled at our pharmacy."

The company said it would back the guarantee by donating $10 to the patient foundation of the physician’s choice for every referral that takes more than two hours to process, as well as $2 for every referral processed within two hours. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Teva introduces generic painkiller

BY Alaric DeArment

NORTH WALES, Pa. — Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.

Teva announced the introduction of oxymorphone hydrochloride tablets.

The drug is a generic version of Endo Pharmaceuticals’ Opana and will be available in the 5 mg and 10 mg strengths in bottles of 100 tablets.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

GSK tests lupus drug in patients with inflammatory blood vessel disorder

BY Alaric DeArment

LONDON — GlaxoSmithKline has started a late-stage clinical trial of a drug in patients with an inflammatory disease that affects the blood vessels.

The drug maker announced the start of a phase-3 trial of Benlysta (belimumab) in patients with vasculitis, a condition in which the body’s immune system attacks blood vessels, leading to inflammation, disruption of blood flow and possible damage to the organs. The drug is being tested in patients with a common form of the disease known as anti-neutrophil cytoplasmic antibodies-positive vasculitis.

The Food and Drug Administration originally approved Benlysta in 2011 for treating lupus.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?